Description
Using rapid NGS testing for trial assignment
in the NCI precision medicine initiative in AML
and MDS (myeloMATCH)
Why should you register now for this webinar?
- Hear an expert discuss the new NCI program in precision medicine (“myeloMATCH”), especially the groundbreaking rapid genetic testing using the NCI Myeloid NGS Assay
- Brought to you by: CAP TODAY
- Moderated by: Bob McGonnagle, Publisher, CAP TODAY
- Presenter: Jerald Radich, MD
- Identify the implications of rapid (<72 hour) cytogenetic, flow cytometry, and NGS mutation testing on enabling expeditious patient assignment to particular myeloMATCH clinical trials based on matching their risk group and genetic lesions to available target therapies.
- Evaluate the NCI Myeloid Assay, a new large NGS panel assay that capitalizes on the automation capabilities of Ion Torrent technology to allow rapid generation of accurate and precise mutation data.
- Understand how myeloMATCH, including the rapid testing strategy, can expedite the development of new therapeutic strategies and potentially enhance patient outcomes.
- Ask questions of our distinguished presenter
The webinar is made possible by a special educational grant from Thermo Fisher Scientific.